DEFA14A: TransCode Therapeutics Regains Nasdaq Compliance, Shares to Remain Listed

TransCode Therapeutics has regained compliance with Nasdaq listing standards, ensuring its stock will remain listed on the exchange.

Summary

• TransCode Therapeutics (Nasdaq: RNAZ) announced that it has regained compliance with all applicable Nasdaq listing standards.
• The company's stock will remain listed and traded on the Nasdaq Stock Market.
• The hearing before the Nasdaq Hearing Panel scheduled for June 25, 2024, has been cancelled.
• TransCode remains subject to a mandatory Nasdaq panel monitor through January 26, 2025.
• The company does not currently expect to pursue a reverse split, given its share price closing over the $1.00 Nasdaq minimum bid price.
• TransCode is focused on treating metastatic disease through RNA therapeutics based on its TTX nanoparticle platform.
• The lead therapeutic candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has regained Nasdaq compliance, avoiding delisting. However, the ongoing monitoring and inherent risks in drug development temper the overall outlook.

Positives

• Regaining Nasdaq compliance avoids delisting and maintains investor confidence.
• The cancellation of the Nasdaq hearing saves the company time and resources.
• The company's share price is above the $1.00 minimum bid price, reducing the need for a reverse split.
• Positive blood test results in connection with the Phase 0 clinical trial and FDA authorization to proceed with the Phase 1 study are positive developments.
• The company is advancing its clinical development programs.

Negatives

• TransCode remains subject to a mandatory Nasdaq panel monitor through January 26, 2025, indicating continued scrutiny.

Risks

• The company faces risks associated with drug discovery and development.
• Clinical trial results may not be consistent with pre-clinical studies or expectations.
• There are risks associated with the timing and outcome of planned regulatory submissions and clinical trials.
• The company faces risks associated with obtaining, maintaining, and protecting intellectual property.
• Competition from other companies developing products for similar uses poses a risk.
• The company's financial condition and its need to obtain additional funding to support its business activities present risks, including the ability to continue as a going concern.
• Dependence on third parties and geopolitical events are also risks.

Future Outlook

The company plans to continue to execute on its ambitious plans to swiftly advance its clinical development programs.

Management Comments

• Tom Fitzgerald, TransCode's Interim Chief Executive Officer and Chief Financial Officer, stated that the company is prepared to continue to execute on its ambitious plans to swiftly advance its clinical development programs.
• Fitzgerald added that the Company does not currently expect to pursue a reverse split.

Industry Context

The announcement highlights the challenges faced by biotech companies in maintaining Nasdaq listing compliance, particularly those in the clinical-stage with significant R&D expenses. Regaining compliance is a positive signal for investors, suggesting improved financial stability or progress in clinical development.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, especially regarding minimum bid price requirements.
• Companies like Geron Corporation and Celldex Therapeutics have faced similar situations and implemented strategies such as reverse stock splits or raising additional capital to regain compliance.
• TransCode's focus on RNA therapeutics aligns with a growing trend in the oncology field, with companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals leading the way in developing RNA-based therapies.

Stakeholder Impact

• Shareholders: Positive impact as the company remains listed on Nasdaq.
• Employees: Positive impact as the company continues to operate and advance its programs.
• Customers: Potential positive impact if the company's therapeutic candidates are successful.
• Suppliers: Continued business relationship with the company.

Next Steps

• Continue advancing clinical development programs.
• Proceed with planned clinical trials for product candidates.
• Focus on obtaining, maintaining, and protecting intellectual property.

Key Dates

Keywords

Nasdaq compliance, RNA therapeutics, TTX-MC138, Metastatic cancer, Clinical trials, Listing standards, TransCode Therapeutics, RNAZ